FDA Drugs · Jul 6, 2026
COVID-19 Update: FDA’s Ongoing Commitment to Transparency for COVID-19 EUAs
FDA is committed to transparency around the EUA process
Latest medical news · page 108
The latest headlines across every section, pulled from official and open-access sources.
FDA Drugs · Jul 6, 2026
FDA Approves First Treatment for COVID-19
FDA approved the antiviral drug Veklury (remdesivir) for adults and pediatric patients 12 years of age and older for the treatment of COVID-19 requiring hospitalization. Veklury is the first treatment for COVID-19 to receive FDA approval.
FDA Drugs · Jul 6, 2026
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use
FDA is warning about a potential drug interaction with remdesivir, which received emergency use authorization to treat hospitalized COVID-19 patients with severe disease.
FDA Drugs · Jul 6, 2026
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
FDA has issued emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
ACC (Cardiology) · Jul 6, 2026
Antihypertensive Medications in Pregnancy and Lactation: A Practical Approach
Effective management of hypertensive disorders of pregnancy is critical to reducing maternal morbidity, improving fetal outcomes, and mitigating long-term cardiovascular risk. This review provides a practical framework for antihypertensive medication selection in pregnancy and the postpartum period.
MedCity News · Jul 6, 2026
A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer appeared first on MedCity News .
FDA Drugs · Jul 6, 2026
Some Homeopathic Products May Put You at Risk
Homeopathic products are marketed without FDA review and may not meet modern standards for safety, effectiveness, quality and labeling. Learn more.
FDA Drugs · Jul 6, 2026
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDA recognizes that patients affected by coronavirus 2019 (COVID-19) are in great need of medicines to treat this disease. To help meet this need, the agency is helping to speed the development of promising therapies through its Coronavirus Treatment Acceleration Program (CTAP).
FDA Drugs · Jul 6, 2026
Ensuring the Safety of Patients in Clinical Trials Studying Investigational New Drugs to Prevent or Treat COVID-19
FDA has a critical role in ensuring the safety of patients in clinical trials studying drugs for the prevention or treatment of COVID-19 that require an investigational new drug (IND) application.
FDA Drugs · Jul 6, 2026
Search for Regulatory References | Drugs
Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and more
FDA Drugs · Jul 6, 2026
FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19
FDA authorizes Gohibic (vilobelimab) injection
FDA Recalls · Jul 6, 2026
Faysu Inc., dba Yusol International Foods Recalls OLA-OLA POUNDED YAM Due to Undeclared Milk Allergen
Fayus Inc., doing business as Yusol International Foods (Sacramento, CA) is voluntarily recalling OLA-OLA POUNDED YAM because the product may contain undeclared milk in the form of sodium caseinate, which is not declared on the label.
FDA Recalls · Jul 6, 2026
Fayus Inc., dba Yusol International Foods Recalls OLA-OLA POUNDED YAM Due to Undeclared Milk Allergen
Fayus Inc., doing business as Yusol International Foods (Sacramento, CA) is voluntarily recalling OLA-OLA POUNDED YAM because the product may contain undeclared milk in the form of sodium caseinate, which is not declared on the label.
ACC (Cardiology) · Jul 6, 2026
Accelerated Aging in the Adult Congenital Heart Disease Population
Aging is a major risk factor for most diseases, and accelerated biological aging is increasingly recognized in many chronic diseases. Chronological age refers to the time that has elapsed since birth, whereas biological age reflects functional, cellular, and tissue age.
MHRA (UK) · Jul 6, 2026
Clinical trials for medicines: ending a clinical trial
Guidance on the process for ending a clinical trial.
MHRA (UK) · Jul 6, 2026
Clinical investigations for medical devices
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
UKHSA (UK) · Jul 6, 2026
Research: Diphtheria: cases among asylum seekers in England, 2022 to 2026
Tables showing confirmed toxigenic C. diphtheriae cases among asylum seekers in England between 2022 and 2026.
MedTech Dive · Jul 6, 2026
Top 10 medtech deals in the first half of 2026
Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.
PLOS Medicine · Jul 6, 2026
Discordance in orphan drug approvals between the U.S. Food and Drug Administration and the European Medicines Agency: A retrospective observational analysis
by Jin Ding, Michael M. Hopkins, Paul A. Martin Background The United States (US) and European Union (EU) have long-established orphan drug regulations to incentivise the development of medicines for rare diseases. While the numbers of orphan approvals have risen rapidly, there is increasing discordance in regulatory outcomes between the US and EU. This discordance primarily stems from two sets of cases: US Food and Drug Administration (FDA) orphan approvals not authorised by the European Medicines Agency (EMA), and FDA orphan approvals with EMA authorisation but without orphan designation. We…
MedCity News · Jul 6, 2026
In Oncology, the Cost Problem Goes Beyond Predictability
Healthcare does not lack the data needed to better understand oncology costs. What it does lack is a consistent way to connect clinical progression with financial impact in a time frame that aligns with strategic planning. The post In Oncology, the Cost Problem Goes Beyond Predictability appeared first on MedCity News .
FDA Drugs · Jul 6, 2026
Upcoming EL-PFDD Meetings
Upcoming EL-PFDD Meetings
FDA Drugs · Jul 6, 2026
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful.
UKHSA (UK) · Jul 6, 2026
UKHSA updates heat health alerts across England
The existing yellow heat-health alert for the East Midlands, West Midlands, East of England, London, South East and South West will be escalated to amber
MedTech Dive · Jul 6, 2026
Medicare slashes 340B payments, broadens site-neutral policies in proposed 2027 payment rule
The rule, released Thursday, builds on Trump administration priorities, including cutting Medicare reimbursement for drugs in the controversial 340B program and equalizing payment between sites of care.